Gland Pharma Limited (NSE:GLAND) — Market Cap & Net Worth
Market Cap & Net Worth: Gland Pharma Limited (GLAND)
Gland Pharma Limited (NSE:GLAND) has a market capitalization of $3.12 Billion (Rs288.46 Billion) as of May 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #4815 globally and #206 in its home market, demonstrating a -2.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gland Pharma Limited's stock price Rs1750.80 by its total outstanding shares 164756423 (164.76 Million). Analyse cash flow conversion of Gland Pharma Limited to see how efficiently the company converts income to cash.
Gland Pharma Limited Market Cap History: 2020 to 2026
Gland Pharma Limited's market capitalization history from 2020 to 2026. Data shows change from $4.13 Billion to $3.12 Billion (-0.52% CAGR).
Index Memberships
Gland Pharma Limited is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY PHARMA
CNXPHARMA
|
$86.64 Billion | 3.60% | #11 of 20 |
|
NIFTY 500
NIFTY500
|
$3.11 Trillion | 0.10% | #191 of 500 |
|
NIFTY MIDCAP 150
NIFTYMIDCAP150
|
$695.80 Billion | 0.45% | #94 of 150 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$1.11 Trillion | 0.28% | #111 of 400 |
|
NIFTY MNC
NIFTYMNC
|
$231.65 Billion | 1.35% | #19 of 30 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.10% | #187 of 750 |
Weight: Gland Pharma Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gland Pharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gland Pharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Gland Pharma Limited's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.44x
Gland Pharma Limited's market cap is 0.44 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $4.13 Billion | $26.33 Billion | $7.73 Billion | 0.16x | 0.53x |
| 2021 | $6.82 Billion | $34.63 Billion | $9.97 Billion | 0.20x | 0.68x |
| 2022 | $2.78 Billion | $44.01 Billion | $12.12 Billion | 0.06x | 0.23x |
| 2023 | $3.39 Billion | $36.25 Billion | $7.81 Billion | 0.09x | 0.43x |
| 2024 | $3.17 Billion | $56.65 Billion | $7.72 Billion | 0.06x | 0.41x |
| 2025 | $3.07 Billion | $56.17 Billion | $6.99 Billion | 0.05x | 0.44x |
Competitor Companies of GLAND by Market Capitalization
Companies near Gland Pharma Limited in the global market cap rankings as of May 4, 2026.
Key companies related to Gland Pharma Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Gland Pharma Limited Historical Marketcap From 2020 to 2026
Between 2020 and today, Gland Pharma Limited's market cap moved from $4.13 Billion to $ 3.12 Billion, with a yearly change of -0.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs3.12 Billion | +1.67% |
| 2025 | Rs3.07 Billion | -3.22% |
| 2024 | Rs3.17 Billion | -6.59% |
| 2023 | Rs3.39 Billion | +22.07% |
| 2022 | Rs2.78 Billion | -59.20% |
| 2021 | Rs6.82 Billion | +65.17% |
| 2020 | Rs4.13 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Gland Pharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.12 Billion USD |
| MoneyControl | $3.12 Billion USD |
| MarketWatch | $3.12 Billion USD |
| marketcap.company | $3.12 Billion USD |
| Reuters | $3.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more